VRE in Saudi Arabia: What You Need to Know About This Emerging Threat
"A comprehensive overview of the prevalence, characteristics, and risk factors of vancomycin-resistant enterococci (VRE) in Saudi Arabia, and what it means for you."
Vancomycin-resistant enterococci (VRE) are Gram-positive bacteria resistant to vancomycin, a powerful antibiotic. Infections caused by VRE lead to longer hospital stays, higher medical costs, and increased mortality rates. Understanding VRE, especially its prevalence and characteristics, is crucial for protecting your health and the health of your community.
In Saudi Arabia, clinical and surveillance reports have highlighted the presence of VRE isolates. This article provides a comprehensive look at the prevalence, characteristics, risk factors, resistance mechanisms, and virulence of VRE isolates associated with infections and colonization in Saudi Arabia.
Whether you're a healthcare professional, someone with underlying health conditions, or simply health-conscious, this information is vital for understanding and mitigating the risks associated with VRE.
The Current Burden of VRE
About 30% of healthcare-associated enterococcal infections are resistant to vancomycin, reducing treatment options. Nearly all VRE infections occur in patients with healthcare exposures, and most infections occur in hospitals. In the United States, the CDC estimated that VRE caused 54,500 infections among hospitalized patients and 5,400 deaths in 2017. California's public health department publishes annual datasets reporting VRE bloodstream infections by hospital and hospital-onset VRE bloodstream infection rates.
Treatment Options and Constraints
Management of VRE bloodstream infections presents challenges involving drug dosing, emerging resistance, and the best treatment for persistent bacteremia and infective endocarditis. Treatment alternatives are constrained, with linezolid and daptomycin among the most commonly used antimicrobial therapies. European guidance resources provide an online directory of documents addressing VRE and antimicrobial resistance. These limitations mean treatment decisions require attention to the infection's clinical context and the possibility of treatment failure.
How VRE Emerged
Vancomycin-resistant enterococci are strains of Enterococcus that resist the antibiotic vancomycin. The first clinical VRE strains were isolated in England and France in 1986, followed by the first documented cases in the United States one year later. Over time, the proportion of enterococcal isolates resistant to vancomycin increased steadily. Researchers have also raised concern that vancomycin-resistance genes could transfer to other gram-positive organisms, including potentially vancomycin-resistant Staphylococcus aureus.
Understanding the Scope of VRE in Saudi Arabia: Prevalence, Risk Factors, and Resistance
VRE was first detected in Saudi Arabia in 1992, and since then, numerous reports have documented its presence. The prevalence rate of VRE infection in Saudi Arabia ranges from 1% to 17.3%. Recent data indicates that hospital-acquired VRE infections are on the rise, signaling an accelerating threat. While the prevalence rate is comparable to some countries like Canada, China, Finland, and Italy, it remains lower than in Portugal, Greece, Ireland, and North America.
- ICU admissions
- Oncology unit stays
- Underlying chronic diseases
- Malignancies
- Chemotherapy and steroid therapy
- Prior antibiotic use
- Central line insertions
What Recent Research Shows
A 2024 review describes VRE infections, particularly bloodstream infections, as imposing substantial mortality and economic burdens, reporting global mortality of 60% to 70%, 23% in India, and an economic burden of $539 million. The same review notes that linezolid and daptomycin are frequently used despite limited clinical trial evidence. A 2025 study reports that antibiotic treatment can significantly disrupt the gut microbiome and promote intestinal colonization by VRE. Another 2025 systematic review identifies VRE across the One Health continuum and evaluates colonization in livestock, food of animal origin, and human populations.
Where the Evidence Remains Limited
VRE management is not a settled problem, and available evidence does not eliminate uncertainty about the best treatment in difficult infections. Reported challenges include emerging resistance, drug dosing, and persistent bacteremia or infective endocarditis. Treatment choices may therefore depend on the clinical situation, local resistance patterns, and the quality of available evidence. Broad conclusions should be made cautiously because outcomes and treatment needs can vary across settings.
Comparing VRE Drugs
Comparisons of daptomycin, linezolid, and tigecycline are commonly presented as study tools for learning about agents used against VRE infections in acute-care settings. Such a table can help organize differences among the drugs, but it is educational rather than a substitute for patient-specific clinical judgment. The source does not establish that one medicine is universally superior. Treatment comparisons should therefore be interpreted alongside the infection's characteristics and the limitations of the available evidence.
The Future of VRE in Saudi Arabia: What Can Be Done?
VRE infections in Saudi Arabia present a significant healthcare challenge due to their association with high mortality rates. The prevalence of VRE varies across different reports, but the overall trend indicates an increasing threat. This underscores the need for robust infection control measures and antibiotic stewardship programs.
Putting the Evidence Together
Taken together, the available evidence portrays VRE as a healthcare-associated threat with limited treatment options and meaningful uncertainty around difficult infections. The most consistent concerns involve resistance, hospital transmission, and the need to choose therapies carefully. Research findings should be interpreted in context because mortality estimates, resistance patterns, and treatment outcomes may differ between populations. Continued surveillance and clinically informed antimicrobial use remain important parts of responding to the threat.
The Next Research Priorities
A 2025 review of vancomycin-resistant Enterococcus faecium focuses on current prevalence, resistance mechanisms, and adaptive traits that have supported its global success. These topics point toward research aimed at understanding how VREfm persists and spreads. In Oman, researchers have characterized enterococcal epidemiology, antimicrobial-resistance trends, and predictors of in-hospital mortality over six years at a tertiary hospital. That work also emphasizes changing surveillance practices and the need to distinguish colonization from infection.
The Wider Systemic Burden
VRE infections, especially bloodstream infections, have been associated with substantial mortality and economic costs. One review reports global mortality of 60% to 70%, 23% in India, and an economic burden of $539 million. It also notes frequent use of linezolid and daptomycin despite inadequate clinical trial evidence. These findings highlight how antimicrobial resistance can create both clinical and health-system pressures.
Living With a Difficult Infection
VRE can create a difficult real-world experience because infections may occur in healthcare settings where patients are already medically vulnerable. Limited treatment options and uncertainty in complicated cases can increase the demands placed on patients, families, and clinical teams. The effects may extend beyond the infection itself through prolonged care needs and concern about transmission. Individual experiences will vary, so these impacts should be understood as potential rather than universal.
Further research is needed to fully understand the economic burden of VRE infections in Saudi Arabia. Enhanced surveillance, diagnostic capabilities, and adherence to infection control protocols are essential to curb the spread of VRE. These steps will help reduce the impact of VRE on patient outcomes and healthcare costs.
By understanding the risks, embracing preventive measures, and supporting ongoing research, we can collectively work towards mitigating the impact of VRE in Saudi Arabia and beyond.